Morgan Stanley's spot Bitcoin ETF, launched in April 2026, has grown rapidly to over $600 million in net assets within five months, driven by $538 million in net inflows and almost no redemptions. This growth highlights the increasing role of major banks in distributing crypto products, providing a trusted and familiar way for traditional investors to access Bitcoin without direct custody or crypto exchanges. The ETF's steady inflows suggest it is viewed as a long-term investment rather than a trading tool, signaling a shift toward more stable institutional demand for Bitcoin. If other major banks follow suit, this could significantly deepen institutional accumulation and reduce reliance on retail speculation in the crypto market.
Morgan Stanley's Bitcoin ETF growth is noted here with Pluang market data as of Sep 15, 2026 20:32 WIB. For readers following cryptocurrency trends, today 18 of 50 major cryptocurrencies on Pluang rose while 31 fell. Notable price changes include BAL (Balancer) at Rp16.297 with a 1-day change of +11.14%, EOS (EOS.IO) at Rp12.649 with +8.13%, and THETA (Theta Network) at Rp3.255 with -7.00%, with THETA showing a Pluang order activity of 79% Sell / 21% Buy.
Tango, a global live-streaming platform, has donated tens of thousands of dollars to support FRIDA Ukraine's mobile cancer screening program. This initiative brings essential cancer detection and preventive healthcare services directly to underserved...
California's upcoming AI safety mandate, effective May 15, 2027, is creating tension with federal military cybersecurity rules under the Defense Federal Acquisition Regulation Supplement (DFARS). Veteran-led engineering groups have developed advanced...
Greg Abel highlighted that every one-point increase in BNSF's profit margin translates to about $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational efficiency has on Berkshire's over...
Genmab announced updated Phase 2 trial results for petosemtamab, an investigational antibody, showing objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer patients. The drug demonstrated promising durabili...
NovaBridge Biosciences announced updated Phase 1b data for givastomig, a bispecific antibody for first-line metastatic gastroesophageal adenocarcinoma, showing durable clinical benefits with an 8 mg/kg dose selected for further development. The data,...
